STEP UP: Semaglutide 7.2 mg High-Dose Trial (2026)

STEP UP is the phase 3b trial that asked a simple question: if you push the semaglutide dose past the 2.4 mg used in Wegovy up to 7.2 mg once weekly, do people lose meaningfully more weight — and is it still tolerable? The answer, published in The Lancet Diabetes & Endocrinology in November 2025, was yes on both counts, but the size of the bonus is more modest than the headlines suggest. In 1,407 adults with obesity and without diabetes, the 7.2 mg dose produced a mean weight loss of 18.7% over 72 weeks, versus 15.6% for the approved 2.4 mg dose and 3.9% for placebo — about a 3-percentage-point gain over standard Wegovy (Wharton 2025 ^[1]). The trade-off: more gastrointestinal side effects (70.8% vs 61.2%) and a new-ish signal of dysaesthesia (altered skin sensation) at the higher dose. This is a detailed walkthrough of who was studied, the exact numbers under each statistical lens, and how honest the “21% weight loss” framing really is. For the standard-dose head-to-head, see tirzepatide vs semaglutide.

The honest summary

• 7.2 mg beats 2.4 mg, but not by a landslide. Mean weight loss was 18.7% vs 15.6% over 72 weeks under the treatment-policy estimand — roughly a 3-percentage-point gain over the dose already in Wegovy (Wharton 2025^[1]).
• The “20.7%” figure is the efficacy estimand. Under the trial-product estimand (the effect if everyone took every dose as intended), 7.2 mg reached 20.7% vs 17.5% for 2.4 mg. Both numbers are real; they answer different questions^[1][5].
• About one in three reached ≥25% weight loss on the high dose. 33.2% of the 7.2 mg group hit ≥25% body-weight loss versus 16.7% with 2.4 mg and 0.0% with placebo (trial-product estimand) — and nearly half reached ≥20% (Wharton 2025^[1]; Novo Nordisk 2025^[5]).
• More dose means more GI side effects. Gastrointestinal adverse events hit 70.8% on 7.2 mg vs 61.2% on 2.4 mg vs 42.8% on placebo — mostly mild-to-moderate nausea, vomiting, diarrhea, constipation (Wharton 2025^[1]).
• A higher-dose signal to watch: dysaesthesia. Altered skin sensation (tingling/numbness, usually transient) was reported by 22.9% on 7.2 mg vs 6.0% on 2.4 mg vs 0.5% on placebo — uncommon at standard doses, clearly dose-related here (Wharton 2025^[1]).
• It is a real molecule decision, not magic. 7.2 mg semaglutide narrows but does not necessarily close the gap with tirzepatide; this trial did not compare the two head-to-head (Jastreboff 2022^[6]).

What STEP UP actually tested

STEP UP (ClinicalTrials.gov NCT05646706) was a randomised, double-blind, placebo-controlled, phase 3b superiority trial run by Novo Nordisk, the maker of semaglutide (Wharton 2025^[1]). It enrolled 1,407 adults with obesity — a body-mass index of at least 30 kg/m² — and without diabetes. Participants were randomly assigned in a 5:1:1 ratio to once-weekly subcutaneous semaglutide 7.2 mg (n=1,005), semaglutide 2.4 mg (n=201), or placebo (n=201), each on top of a lifestyle intervention (reduced-calorie diet plus increased physical activity), for 72 weeks. The lopsided randomisation puts most participants on the experimental dose — useful for characterising the new dose's safety, less so for a clean efficacy comparison, which is why the 2.4 mg and placebo arms are smaller.

The population was squarely “real-world obese”: mean age 47 years, mean body weight 113.0 kg (about 249 lb), and a high mean BMI of 39.9 kg/m² — close to the threshold for class III (severe) obesity. That matters when you read the percentages: a 18.7% loss off a 113 kg starting weight is roughly 21 kg (about 47 lb). The coprimary endpoints were the percentage change in body weight and the proportion of participants achieving a weight reduction of 5% or greater, both for semaglutide 7.2 mg versus placebo (Wharton 2025^[1]).

The headline efficacy numbers — under two different lenses

Modern obesity trials report results under two “estimands,” and STEP UP is a textbook case of why the distinction matters. The treatment-policy estimand measures the effect regardless of whether people stayed on the drug — it counts everyone, including those who stopped early or never adhered, so it reflects what a population actually achieves. The trial-product estimand estimates the effect if everyone had taken every dose as intended, with no discontinuation — the “pharmacological ceiling.” The press release led with the larger trial-product figure; the peer-reviewed paper's primary analysis used the more conservative treatment-policy figure (Wharton 2025^[1]; Novo Nordisk 2025^[5]).

Read the table honestly. Under either lens, the 7.2 mg dose was statistically superior to both placebo and the approved 2.4 mg dose for weight loss (p<0.0001 vs placebo). But the incremental benefit over standard Wegovy is about 3 percentage points (18.7% vs 15.6%, treatment-policy) — meaningful for someone who has plateaued on 2.4 mg, but not a doubling. The much larger gap is against placebo, which is expected. The widely quoted “21% weight loss” is the trial-product 20.7% figure rounded up; it describes the best-case adherent patient, not the average enrolled patient.

Proportions hitting the big weight-loss thresholds

Average percentages hide the responders. STEP UP reported the share of participants crossing each weight-loss threshold, and this is where the high dose looks most impressive (trial-product estimand, Wharton 2025^[1]; Novo Nordisk 2025^[5]):

• ≥5% loss: over 90% of the 7.2 mg group — the coprimary endpoint, easily met versus placebo.
• ≥20% loss: nearly half of those on 7.2 mg reached at least a fifth of their body weight gone.
• ≥25% loss: 33.2% on 7.2 mg versus 16.7% on 2.4 mg and 0.0% on placebo — roughly double the proportion of standard Wegovy hitting this once-bariatric-surgery-territory threshold.

The odds-ratio framing in the paper is dramatic but should be read carefully: the 7.2 mg group was vastly more likely than placebo to reach ≥25% loss (odds ratio ~127, reflecting that essentially nobody on placebo got there), and about 2.4 times more likely than the 2.4 mg group to reach ≥25%, and 1.8 times more likely to reach ≥20% (Wharton 2025^[1]). Those dose-versus-dose ratios — not the giant placebo ratios — are the numbers that tell you what the extra milligrams buy.

The safety and tolerability trade-off

More semaglutide means more of semaglutide's familiar side effects. Gastrointestinal adverse events — nausea, vomiting, diarrhea, constipation — were reported by 70.8% (711 of 1,004) on 7.2 mg, versus 61.2% (123 of ~201) on 2.4 mg and 42.8% (86 of ~201) on placebo. As in earlier STEP trials, most were mild to moderate and clustered during dose escalation rather than persisting through maintenance (Wharton 2025^[1]). Serious adverse events occurred in 6.8% (68 participants) of the 7.2 mg group — within the range seen across the obesity-trial program.

Two things the trial did not show are worth stating plainly. First, it did not surface a new or unexpected serious safety signal beyond the known GLP-1 class profile — the higher dose mostly amplified what semaglutide already does. Second, more side effects do not automatically mean more dropouts; the paper frames the 7.2 mg dose as retaining a “favourable risk–benefit profile,” meaning the efficacy gain was judged to outweigh the added GI burden for the population studied. Individual tolerance, of course, varies — which is the entire reason dose escalation is slow.

How much does the extra dose really add?

This is the question worth being honest about. The jump from 2.4 mg to 7.2 mg roughly tripled the dose but added only about 3 percentage points of average weight loss (15.6% → 18.7%, treatment-policy). That is the signature of a flattening dose-response curve: by 2.4 mg, semaglutide is already capturing most of the achievable effect, and each additional milligram returns less. The clearest beneficiaries are at the tails — people who never reached their goal on 2.4 mg, or who specifically need to cross the ≥20–25% threshold (e.g., for an obesity-related complication). For them, doubling the share reaching ≥25% (16.7% → 33.2%) is a substantial clinical difference.

STEP UP also can't answer the comparison many readers actually care about: 7.2 mg semaglutide versus tirzepatide. There was no tirzepatide arm. In the separate SURMOUNT-1 program, tirzepatide produced mean weight losses in the low-to-mid 20% range at its highest dose (Jastreboff 2022^[6]), so 7.2 mg semaglutide narrows the gap with tirzepatide without a head-to-head proving it closes it. The only randomised semaglutide-vs-tirzepatide data come from SURMOUNT-5, which used 2.4 mg semaglutide, not 7.2 mg — so it doesn't settle the high-dose question either. Treat cross-trial comparisons as hypotheses, not verdicts. For the standard-dose comparison, see Wegovy vs Ozempic.

What STEP UP means for patients and prescribers

• It is the evidence base for a higher-dose semaglutide option. STEP UP and STEP UP T2D are the trials behind a high-dose semaglutide formulation; if and when one is approved or prescribed, this is the data justifying it (Wharton 2025^[1]; Lingvay 2025^[2]).
• Best suited to plateaued or higher-target patients. The marginal benefit over 2.4 mg is modest on average but real at the high-response thresholds, making 7.2 mg most logical for people who have stalled below goal on standard Wegovy.
• Expect a heavier GI escalation and counsel on dysaesthesia. The added nausea/vomiting burden and the ~23% dysaesthesia rate are the practical costs; slow titration and upfront counselling matter more at this dose.
• Diabetes changes the math. These obesity-population results don't transfer to people with type 2 diabetes, who were studied separately in STEP UP T2D with smaller weight loss (Lingvay 2025^[2]).
• Lifestyle was still in the protocol. Every arm received a reduced-calorie diet and activity counselling; the drug effect is on top of that, not instead of it.
• It does not crown a winner versus tirzepatide. No head-to-head was done at 7.2 mg; cross-trial numbers are suggestive only (Jastreboff 2022^[6]).

Bottom line

STEP UP showed that pushing semaglutide to 7.2 mg once weekly produces more weight loss than the approved 2.4 mg dose in adults with obesity — 18.7% vs 15.6% on average (treatment-policy), or 20.7% vs 17.5% if everyone adhered perfectly (trial-product), with about a third of high-dose patients losing ≥25% of their body weight versus one in six on standard Wegovy (Wharton 2025^[1]; Novo Nordisk 2025^[5]). The incremental average benefit over 2.4 mg is real but modest — roughly 3 points — reflecting a flattening dose-response curve, and it comes at the cost of more gastrointestinal events (70.8% vs 61.2%) and a notable dose-related dysaesthesia signal (22.9% vs 6.0%). For someone stalled on standard Wegovy or chasing a higher weight-loss target, 7.2 mg is a meaningful additional rung on the ladder; for most people already doing well on 2.4 mg, it is an incremental gain to weigh against added side effects. As always, the decision belongs with a clinician who knows your full picture. For how weight loss interacts with muscle, see semaglutide and muscle mass.

This article is educational and is not medical advice. Every trial number above is sourced to the peer-reviewed STEP UP publication in The Lancet Diabetes & Endocrinology (PMID 40961952) or the trial sponsor's topline release, and was verified against the live PubMed database before publication. Semaglutide 7.2 mg is a higher dose than the 2.4 mg in approved Wegovy; do not adjust your dose without your prescriber.